Solventum Corporation is a global healthcare company that develops, manufactures, and commercializes solutions leveraging material science, data science, and digital capabilities. The company operates through three reportable segments: MedSurg, which provides negative pressure wound therapy, advanced wound dressings, surgical supplies, and sterilization assurance; Dental Solutions, offering orthodontic products, restorative cements, and bonding agents; and Health Information Systems, providing software for speech recognition, coding automation, and data visualization. Solventum serves a diverse customer base including multidisciplinary hospitals, local clinics, dental practices, and healthcare systems worldwide. The company acquired Acera Surgical in 2025 and divested its Purification and Filtration business to Thermo Fisher Scientific. Solventum focuses on improving patient care, safety, and administrative efficiency across the prevention, diagnosis, treatment, and recovery stages of the patient journey.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage solventum.com
Sector Healthcare IR page investors.solventum.com
Tags
wound care, orthodontics, healthcare software, speech recognition, surgical supplies, sterilization, dental materials, revenue cycle management, clinical documentation, bioscience, Acera Surgical, Clarity Precision Grip Attachments, Clarity Attachment Material, Clarity Composite Veneers, Solventum 360 Encompass System, Solventum Cloud Platform, Solventum Fluency platform, VH202, EtO
Press page investors.solventum.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 14.982B
Market cap (USD) $ 14.982B
P/E 97.94
PEG 19.47
P/BV 3.12
P/S 1.84
P/OCF 48.33
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 38.9%
ROI 15.4%
ROIC 19.6%
Profit margin 18.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 5.0%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 105.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 36
Quality score 50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 8.325B 8.254B 8.197B 8.13B 8.171B
Net profit 1.556B 479M 1.346B 1.343B 1.46B
Free cash flow -10M 805M 1.625B 1.428B 1.925B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 79.24 66.06 — — —
Price performance 12m 0.2 — — — —

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 1.31B 1.04B 1.03B
↳ YoY growth -20.5% -1.0%
Borrowings, current (USD) — — 0.00 200M 0.00
Borrowings, non-current (USD) — — 0.00 7.81B 5.04B
Lease liabilities (USD) — — 98M 173M 212M
Cash and deposits (USD) 91M 61M 194M 762M 878M
Intangible assets (USD) — — 2.9B 2.54B 2.59B
Right-of-use assets (USD) — — 98M 176M 214M
Net debt (borrowings + leases - cash) (USD) — — -194M 7.42B 4.37B
Cash flow detail
Operating cash flow (USD) — 1.68B 1.92B 1.19B 369M
Purchases of property, plant and equipment (USD) — -251M -290M -380M -379M
Change in receivables (cash effect) (USD) — -32M -129M 43M 34M
Change in inventories (cash effect) (USD) — -82M 23M -132M -139M
Change in payables (cash effect) (USD) — 25M 105M 266M 104M
Interest paid (cash effect) (USD) — 0.00 0.00 -287M -442M
Income taxes paid (cash effect) (USD) — 0.00 0.00 -244M -181M
Share-based compensation (USD) — 37M 39M 112M 161M
Operating cash flow before change in receivables (USD) — 1.71B 2.04B 1.14B 335M
Free cash flow (OCF - PPE - intangibles) (USD) — 1.43B 1.63B 805M -10M
Income detail
Research and development expense (USD) — 767M 758M 775M 739M
Total comprehensive income (USD) — 1.05B 1.47B 291M 1.99B
Comprehensive income to owners (USD) — 1.05B 1.47B 291M 1.99B
Reported Feb 28, 2025 Feb 28, 2025 Feb 28, 2025 Feb 28, 2025 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 05, 2026 4:05pm EST Download as PDF

Related Documents

Earnings WebcastAudio Transcript

PresentationPDF

Shareholder LetterPDF

Quarterly Financial UpdatePDF

10-QHTML XBRL Zip

  • Reported sales decreased 7.0%; organic sales decreased 2.8%, reflecting the expected 630 basis point (bps) impact of prior quarter advance orders placed ahead of the planned ERP system cutover during the current quarter
  • Expects full-year organic sales growth toward the high end of +2.5% to +3.0% range
  • Increases full-year adjusted EPS guidance to $7.20 to $7.30

EAGAN, Minn., Nov. 5, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2026.

Solventum Logo

Third Quarter 2026 Highlights

  • Sales of $1.9 billion, decreased 7.0% on a reported basis; a decrease of 2.8% on an organic basis
  • GAAP diluted earnings per share of $(0.07); adjusted diluted earnings per share of $1.45, a 3.6% decrease
  • Operating cash flow of $177 million; free cash flow of $97 million
  • Have exited ~90% of 3M transition service agreements; ERP system cutovers complete

"Solventum delivered third quarter results ahead of our expectations, with every segment contributing, even as we completed our largest ERP cutover; we expect to be near the top end of our full-year organic sales growth range and are raising our full-year adjusted earnings per share outlook," said Bryan Hanson, chief executive officer of Solventum. "With separation now more than 90% complete and our growth drivers gaining momentum, we are well positioned to accelerate sales growth and expand margins. We have differentiated innovation, a strong pipeline of new products and a significant opportunity to expand penetration of our existing brands with customers we already serve."

Third Quarter and First Nine Months 2026 Financial Results*

Scroll to view ↔

Three months ended September 30, Nine Months Ended September 30,
(Dollars in millions, except per shareamounts) 2026 2025 Year-over-yearchange 2026 2025 Year-over-yearchange
Net sales $      1,949 $      2,096 (7.0) % $      6,165 $      6,327 (2.6) %
Selling, general and administrativeexpenses $         813 $         780 4.2 % $      2,567 $      2,321 10.6 %
Research and developmentexpenses $         181 $         183 (1.1) % $         548 $         564 (2.8) %
Operating income margin 3.5 % 80.6 % (7,710) bps 5.3 % 32.5 % (2,720) bps
Adjusted operating income margin1 19.9 % 20.6 % (70) bps 22.8 % 20.7 % 210 bps
Net income (loss) $          (12) $      1,266 (100.9) % $           93 $      1,493 (93.8) %
Diluted earnings per share $       (0.07) $        7.22 (101.0) % $        0.54 $        8.53 (93.7) %
Adjusted diluted earnings pershare1 $        1.45 $        1.50 (3.6) % $        5.48 $        4.53 20.9 %
Net cash provided by (used in)operating activities $         177 $           75 136.0 % $         215 $         274 (21.5) %
Free cash flow1 $           97 $          (22) 540.9 % $          (32) $          (42) 23.8 %
*Year-over-year changes may not calculate due to rounding.
1 Represents non-GAAP financial measure; see the "Non-GAAP Financial Measures" section for applicable information

Discussion of Third Quarter Results

All comparisons are to the prior year period unless otherwise noted

  • Organic sales decline of 2.8% in the quarter reflects the expected 630 bps reversal of Q2 2026 advance orders placed ahead of the planned ERP system cutover during Q3 2026.
  • GAAP and adjusted gross margin both increased, primarily driven by portfolio optimization, mix benefits and savings programs, partially offset by inflation and tariffs.
  • GAAP selling, general and administrative expenses increased primarily due to higher operating expenses associated with restructuring.
  • GAAP operating income margin decreased, primarily driven by prior year's gain on sale of the purification & filtration business and higher current year restructuring costs. Adjusted operating income margin decreased primarily due to the expected impact of Q2 2026 advance orders placed ahead of the planned ERP system cutover during Q3 2026.
  • Operating cash flow for the quarter was $177 million and free cash flow was $97 million, ahead of expectations driven by IEEPA tariff refund.

Other Business and Operational Highlights

  • Received FDA 510(k) clearance for the combined use of Restrata and V.A.C. Therapy, bringing together two advanced wound care technologies and demonstrating continued progress integrating Acera Surgical's technology into Solventum's Advanced Wound Care portfolio.
  • Earned a 2026 Red Dot Award for Product Design for the Solventum Filtek™ Composite Warmer with the device noted for its clean, compact form that combines performance with flexibility and features a simplified user interface to keep operation clear and straightforward, making it easy for dental providers to use.
  • The Bair Hugger™ warming system was named the 2026 Coolest Thing Made in Minnesota, an annual recognition presented by the Minnesota Chamber of Commerce and the Minnesota Manufacturers' Council.  Used in healthcare facilities around the world, the Bair Hugger warming system is recognized as a standard of care in forced-air warming helping drive better patient outcomes and lower complication-related costs.

Scroll to view ↔

Segment and Total Company Net Sales for Third Quarter and First Nine Months*
Three months endedSeptember 30, Increase/(Decrease)
(Dollars in millions) 2026 2025 Reportedgrowth Currencyimpact Constantcurrency****2 Other****3 Organicgrowth
Advanced Wound Care $          528 $          485 8.9 % 0.2 % 8.7 % 7.2 % 1.5 %
Infection Prevention andSurgical Solutions 683 722 (5.3) 0.4 (5.7) — (5.7)
MedSurg 1,211 1,206 0.4 0.3 0.1 2.9 (2.8)
Dental Solutions 317 340 (6.7) 0.7 (7.4) — (7.4)
Health Information Systems 356 345 3.3 0.1 3.2 (1.2) 4.4
Total reportable segmentnet sales 1,884 1,891
Purification and Filtration — 128 NM NM NM NM NM
All Other4 64 77 (15.9) (0.4) (15.5) — (15.5)
Total Company $       1,949 $       2,096 (7.0) % 0.3 % (7.3) % (4.5) % (2.8) %
Nine months endedSeptember 30, Increase/(Decrease)
(Dollars in millions) 2026 2025 Reportedgrowth Currencyimpact Constantcurrency****2 Other****3 Organicgrowth
Advanced Wound Care $       1,561 $       1,400 11.5 % 1.2 % 10.3 % 6.7 % 3.6 %
Infection Prevention andSurgical Solutions 2,256 2,182 3.4 1.6 1.8 — 1.8
MedSurg 3,818 3,581 6.6 1.5 5.1 2.6 2.5
Dental Solutions 1,067 1,006 6.0 2.3 3.7 — 3.7
Health Information Systems 1,052 1,012 4.0 0.4 3.6 (1.2) 4.8
Total reportable segmentnet sales 5,937 5,600
Purification and Filtration — 497 NM NM NM NM NM
All Other4 227 230 (1.0) 1.1 (2.1) — (2.1)
Total Company $       6,165 $       6,327 (2.6) % 1.3 % (3.9) % (6.8) % 2.9 %
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. "NM" reflects results considered not meaningful due to sale of the Purification and Filtration business in September 2025
2__Constant currency represents the change in net sales absent the impact on sales from foreign currency translation
3__Other represents sales impact from acquisitions and divestitures measured separately for the first 12 months post-transaction. Acquisitions include sales from the December 2025 acquisition of Acera. Divestitures primarily represents lost sales from the Company's Purification and Filtration business that was sold in September 2025
4__All Other includes the Drinking Water business, which was previously reported within Purification and Filtration, and sales related to product supplied to 3M and other supply agreements related to legacy 3M business and assumed by the Company at Spin-Off

Full-Year 2026 Guidance

Solventum is updating its full year 2026 guidance as follows:

  • Increased organic sales growth range toward the high end of +2.5% to +3.0% (toward the high end of +3.5% to +4.0% excluding ~100 bps of SKU exit impact)
  • Increased adjusted EPS range to $7.20 to $7.30; from prior range of $7.10 to $7.20
  • Affirming free cash flow in the range of $200 million to $300 million

Organic sales, adjusted diluted EPS and free cash flow amounts included in Solventum's full-year guidance are non-GAAP financial measures. Solventum does not provide reconciliations of the forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items, such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items.

See the "Non-GAAP Financial Measures" section for explanations of our non-GAAP financial measures.

Earnings Conference Call

Solventum will host a conference call today, November 5, at 4:30 p.m. Eastern Time to discuss its third quarter financial results and fiscal year 2026 outlook. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers, using the conference ID 6342275.

A replay of the webcast, along with the earnings press release, slides highlighting the results and supplemental financial disclosures, will also be available at the same link on the Investor Relations section of the Company's website.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934 that are subject to risks and uncertainties. Solventum intends the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in those sections. Forward-looking statements include all statements that are not historical facts, but instead represent only Solventum's beliefs regarding future goals, plans and expectations about its prospects for the future and other events, many of which, by their nature, are inherently uncertain and outside of Solventum's control. Forward-looking statements include those containing such words as "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "potential," "predicts," "projects," "seeks," "sees," "should," "targets," "will," "would," or other words of similar meaning in connection with any discussion of future operating or financial performance, business plans or prospects, Solventum's review of strategic alternatives for its health information systems business, or the potential benefits of any such strategic alternatives or transaction.

Among the factors that could cause actual results to differ materially from those described in our forward-looking statements are the following: (1) whether Solventum will be able to identify or develop any strategic alternatives for Solventum's health information systems business; (2) Solventum's ability to execute on material aspects of any strategic alternatives that are identified and pursued; (3) whether Solventum can actually achieve the potential benefits of any strategic alternatives; (4) the occurrence of any event, change or other circumstances that could give rise to the abandonment of the review of strategic alternatives or pursuit of a different structure or strategic alternative; (5) uncertainties as to the timing of the review of strategic alternatives; (6) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises and other events beyond Solventum's control; (7) operational execution risks; (8) damage to Solventum's reputation or its brands; (9) risks from acquisitions, strategic alliances, divestitures and other strategic events; (10) Solventum's business dealings involving third-party partners in various markets; (11) Solventum's ability to access the capital and credit markets and changes in Solventum's credit ratings; (12) exposure to interest rate and currency risks; (13) the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (14) reduction in customers' research budgets or government funding; (15) the timing and market acceptance of Solventum's new product and service offerings; (16) ongoing working relationships with certain key healthcare professionals; (17) changes in reimbursement practices of governments or private payers or other cost containment measures; (18) Solventum's ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions and disruptive factors; (19) legal and regulatory proceedings and legal compliance risks (including third-party risks) with regards to antitrust, FCPA and other anti-bribery laws, environmental laws, anti-kickback and false claims laws, privacy laws, product liability claims, tax laws, and other laws and regulations in the United States and other countries in which Solventum operates; (20) potential liabilities related to per-and polyfluoroalkyl substances, collectively known as "PFAS"; (21) risks related to the highly regulated environment in which Solventum operates; (22) risks associated with product liability claims; (23) climate change and measures to address climate change; (24) security breaches and other disruptions to information technology infrastructure; (25) artificial intelligence risks; (26) Solventum's failure to obtain, maintain, protect or effectively enforce its intellectual property rights; (27) pension and postretirement obligation liabilities; (28) Solventum's separation from 3M and performance as a standalone company, including the tax-free nature of the spin and its ability to execute on its short- and long-range plans and capital allocation strategies; (29) restructuring programs, and (30) our ability to successfully deploy our new ERP system and any disruption to our business as a result of such deployment, and other risks and uncertainties described in Solventum's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

The above list is not exhaustive or necessarily set forth in the order of importance. Forward-looking statements are based on certain assumptions and expectations of future events and trends, and actual future results and trends may differ materially from historical results or those reflected in any such forward-looking statements depending on a variety of factors. A further description of these factors is located under "Cautionary Note Concerning Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information, future events or otherwise, except as required by applicable law.

Non-GAAP Financial Measures

In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adjusted measures are not in accordance with, nor are they a substitute for, GAAP measures. These non-GAAP financial measures are supplemental measures of our performance and our liquidity that we believe help investors understand our underlying business performance and Solventum uses these measures as an indication of the strength of Solventum and its ability to generate cash.

Solventum calculates forward-looking non-GAAP financial measures, including organic sales growth, adjusted gross margin, adjusted operating income, adjusted operating income margin, adjusted effective tax rate, adjusted diluted earnings per share and free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. Solventum does not provide reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable GAAP measures as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items. The timing and amounts of these items are uncertain and could have a material impact on Solventum's results in accordance with GAAP.

The Q3 2026 financial statements and financial information, including reconciliations of non-GAAP financial measures, are available on Solventum's website: investors.solventum.com .

About Solventum

At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com .

Scroll to view ↔

Solventum CorporationCONDENSED CONSOLIDATED STATEMENTS OF INCOME*(Dollars in millions, except per-share data)(Unaudited)
Three months endedSeptember 30, Nine months endedSeptember 30,
2026 2025 2026 2025
Net sales of product $      1,431 $      1,594 $      4,642 $      4,859
Net sales of software and rentals 518 502 1,522 1,468
Total net sales 1,949 2,096 6,165 6,327
Cost of product 771 847 2,373 2,547
Cost of software and rentals 116 114 347 356
Gross profit 1,062 1,135 3,444 3,424
Selling, general and administrative expenses 813 780 2,567 2,321
Research and development expenses 181 183 548 564
Gain on sale of business — (1,518) — (1,518)
Operating income 68 1,690 329 2,057
Interest expense, net 68 89 194 296
Loss on debt extinguishment, net — 82 — 82
Other expense (income), net 10 5 23 24
Income (loss) before income taxes (11) 1,514 112 1,655
Provision for (benefit from) income taxes 1 248 19 162
Net income (loss) $          (12) $      1,266 $           93 $      1,493
Earnings per share:
Basic earnings per share $       (0.07) $        7.26 $        0.54 $        8.58
Diluted earnings per share (0.07) 7.22 0.54 8.53
Weighted-average number of shares outstanding:
Basic 170.8 174.3 172.6 174.0
Diluted 170.8 175.4 173.6 175.1
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum

Scroll to view ↔

Solventum CorporationCONDENSED CONSOLIDATED BALANCE SHEETS*(Dollars in millions, except per-share data)(Unaudited)
September 30, December 31,
2026 2025
Assets
Current assets
Cash and cash equivalents $           451 $          878
Accounts receivable — net of allowances of $86 and $87 1,364 1,034
Due from related parties 27 150
Inventories
Finished goods 613 636
Work in process 235 201
Raw materials and supplies 254 229
Total inventories 1,102 1,066
Other current assets 750 731
Total current assets 3,692 3,859
Property, plant and equipment — net 1,593 1,326
Goodwill 5,616 5,704
Intangible assets — net 2,317 2,592
Other assets 946 814
Total assets $      14,165 $      14,294
Liabilities
Current liabilities
Short-term borrowings and current portion of long-term debt $           507 $             —
Accounts payable 808 687
Due to related parties 152 435
Unearned revenue 596 621
Other current liabilities 1,511 1,393
Total current liabilities 3,575 3,136
Long-term debt 4,561 5,035
Pension and postretirement benefits 355 363
Deferred income taxes 154 164
Finance leases 206 —
Other liabilities 508 547
Total liabilities $        9,360 $        9,245
Equity
Common stock, par value $0.01 per share, 750,000,000 shares authorized $               2 $               2
Shares - September 30, 2026: issued: 175,303,750; outstanding: 169,956,897
Shares - December 31, 2025: issued and outstanding: 173,490,864
Additional paid-in capital 3,982 3,876
Retained earnings 1,891 1,797
Treasury stock, at cost (403) —
Shares - September 30, 2026: 5,346,853
Shares - December 31, 2025: —
Accumulated other comprehensive income (loss) (667) (625)
Total equity 4,805 5,049
Total liabilities and equity $      14,165 $      14,294
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum

Scroll to view ↔

Solventum CorporationCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS*(Dollars in millions)(Unaudited)
Nine months ended September 30,
2026 2025
Cash flows from operating activities
Net income $            93 $        1,493
Adjustments to reconcile net income to net cash provided by (used in) operatingactivities
Depreciation and amortization 404 372
Pension and postretirement benefit expense 40 49
Stock-based compensation expense 131 124
Gain on sale of business — (1,518)
Purification and Filtration Transaction costs — (86)
Deferred income taxes (139) (47)
Changes in assets and liabilities
Accounts receivable (340) 36
Due from related parties 123 37
Inventories (42) (134)
Accounts payable 111 74
Due to related parties (300) 18
Accrued compensation (58) (9)
All other operating activities — net 192 (135)
Net cash provided by operating activities 215 274
Cash flows from investing activities
Purchases of property, plant and equipment (247) (316)
Proceeds from sale of business — 3,870
Other — net 3 (12)
Net cash (used in) provided by investing activities (244) 3,542
Cash flows from financing activities
Repayment of debt — (2,970)
Proceeds from debt, net of issuance costs 46 —
Net transfers from (to) 3M 2 (21)
Purchases of treasury stock (403) —
Other — net (46) 49
Net cash used in financing activities (401) (2,942)
Effect of exchange rate changes on cash and cash equivalents 1 6
Net (decrease) increase in cash and cash equivalents (428) 880
Cash and cash equivalents at beginning of period 878 762
Cash and cash equivalents at end of period $          451 $        1,642
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum

**Solventum Corporation
****BUSINESS SEGMENTS – (CONTINUED)*
**(Unaudited)

The Company's operating activities are primarily managed through three segments: MedSurg, Dental Solutions and Health Information Systems.

  • MedSurg provides:
    • Advanced wound care products such as negative pressure wound therapy, advanced wound dressings, advanced skin care and synthetic tissue matrices; and
    • Infection prevention and surgical solutions products, such as IV site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer ("OEM").
  • Dental Solutions provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents that span the "life of the tooth," including products designed for preventative dental care, direct and indirect restoration, and broad orthodontic needs.
  • Health Information Systems provides healthcare systems with software solutions — including computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms — that are designed to eliminate revenue cycle waste, create more time for patient care, and support value-based care.

Purification and Filtration consists of filters and membranes for biopharmaceutical and medical technologies, as well as microelectronics and food and beverage that were reported prior to the sale of the business in September 2025.

All Other primarily consists of our drinking water filtration business that was retained after the sale of the Purification and Filtration Business. All Other also includes sales and cost of sales related to our agreements to supply 3M and other supply agreements assumed by the Company at Spin-Off related to legacy 3M businesses, which were historically included within Corporate and Unallocated.

Scroll to view ↔

BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES*
Three months ended September 30, 2026 Three months ended September 30, 2025
(Dollars in millions) Net sales Operatingincome Operatingmargin % Net sales Operatingincome Operatingmargin %
Advanced Wound Care $        528 $        485
Infection Prevention and SurgicalSolutions 683 722
MedSurg 1,211 $       194 16.0 % 1,206 $        203 16.8 %
Dental Solutions 317 64 20.1 340 87 25.7
Health Information Systems 356 149 41.7 345 134 38.8
Total reportable segment netsales and operating income 1,884 406 1,891 424
Purification and Filtration — — NM 128 26 20.1
All Other 64 10 16.0 77 12 15.6
Amortization expense (90) (77)
Corporate and unallocated (259) 1,305
Total Company $     1,949 $         68 3.5 % $     2,096 $     1,690 80.6 %
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum
BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES*
Nine months ended September 30, 2026 Nine months ended September 30, 2025
(Dollars in millions) Net sales Operatingincome Operatingmargin % Net sales Operatingincome Operatingmargin %
Advanced Wound Care $     1,561 $     1,400
Infection Prevention and SurgicalSolutions 2,256 2,182
MedSurg 3,818 $       710 18.6 % 3,581 619 17.3 %
Dental Solutions 1,067 281 26.4 1,006 262 26.1
Health Information Systems 1,052 424 40.3 1,012 363 35.8
Total reportable segment netsales and operating income 5,937 1,416 5,600 1,244
Purification and Filtration — — NM 497 96 19.3
All Other 227 41 17.8 230 31 13.5
Amortization expense (271) (235)
Corporate and unallocated (856) 921
Total Company $     6,165 $       329 5.3 % $     6,327 2,057 32.5 %
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum

**Solventum Corporation
****SUPPLEMENTAL FINANCIAL INFORMATION
****NON-GAAP MEASURES
**(Unaudited)

In addition to reporting financial results in accordance with U.S. GAAP, the Company uses non-GAAP financial measures to supplement the financial measures prepared in accordance with U.S. GAAP. These include (1) adjusted gross margin, adjusted operating income and adjusted operating income margin, (2) adjusted diluted earnings per share, and (3) free cash flow. Management believes that these non-GAAP financial measures are useful in evaluating current performance and focusing management on our underlying operational results.

There are limitations to the use of the non-GAAP financial measures presented in this information statement. These non-GAAP financial measures are not prepared in accordance with U.S. GAAP nor do they have any standardized meaning under U.S. GAAP. In addition, other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way we calculate such measures. Accordingly, our non-GAAP financial measures may not be comparable to such similarly titled non-GAAP financial measures used by other companies. Management cautions you not to place undue reliance on these non-GAAP financial measures, but instead to consider them with the most directly comparable U.S. GAAP measure. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation. These non-GAAP financial measures should be considered supplements to, not substitutes for, or superior to, the corresponding financial measures calculated in accordance with U.S. GAAP.

The tables below reconcile our non-GAAP financial measures to the nearest financial measure that is in accordance with U.S. GAAP for the periods presented.

Adjusted Gross Margin, Adjusted Operating Income, Adjusted Operating Income Margin and Adjusted Earnings Per Share (Non-GAAP measures)

Adjusted gross margin, adjusted operating income and adjusted operating income margin are not defined under U.S. GAAP. Therefore, they should not be considered a substitute for earnings data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. Solventum defines adjusted gross margin as gross margin excluding the effects of restructuring costs, Spin-Off and separation-related costs, and acquisition and divestiture-related costs. Solventum defines adjusted operating income as operating income excluding the effects of amortization, restructuring costs, Spin-Off and separation-related costs, certain litigation-related costs, and acquisition and divestiture-related activities. Adjusted operating income margin is adjusted operating income divided by the U.S GAAP measure total net sales for the same period. The Company believes adjusted gross margin, adjusted operating income and adjusted operating income margin provide investors with visibility into the Company's unleveraged, pre-tax operating results and reflects underlying financial performance. However, adjusted gross margin and adjusted operating income should not be construed as inferring that the Company's future results will be unaffected by the items for which the measure adjusts.

Adjusted diluted earnings per share is not defined under U.S. GAAP. Therefore, it should not be considered a substitute for earnings data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. Solventum defines adjusted diluted earnings per share as net income excluding the after-tax effects of amortization, restructuring costs, Spin-Off and separation-related costs, certain litigation-related costs, acquisition and divestiture-related activities, and loss on debt extinguishment, net. The Company believes adjusted earnings per share provides investors with improved comparability of underlying operating results and a further understanding and additional transparency regarding how the Company evaluates the business. However, adjusted earnings per share should not be construed as inferring that the Company's future results will be unaffected by the items for which the measure adjusts.

Scroll to view ↔

Solventum CorporationSUPPLEMENTAL FINANCIAL INFORMATIONNON-GAAP MEASURES – (CONTINUED)*(Unaudited)
Three months ended September 30, 2026
(Dollars in millions, except pershare amounts) GAAP Amortization ofacquisition-relatedintangibleassets Restructuringcosts (a) 3M spin-off andseparation-relatedcosts (b) Certainlitigation-relatedcosts (c) Acquisition anddivestiture-related (d,e) Non-GAAP
Net sales $      1,949 — — — — — $      1,949
Cost of sales (5) $         887 — (11) (38) — 1 $         837
Gross margin % 54.5 % — % 0.6 % 2.0 % — % — % 57.1 %
Selling, general and administrativeexpenses $         813 (42) (37) (115) (7) (17) $         595
Research and developmentexpenses $         181 (48) (1) (3) — — $         130
Operating expenses (6) $         994 (90) (38) (118) (7) (17) $         725
Operating Income $           68 90 50 157 7 16 $         387
Operating income margin % 3.5 % 4.6 % 2.5 % 8.0 % 0.4 % 0.8 % 19.9 %
Non-operating expense (income),net (7) $           79 — — — — — $           79
Income (loss) before income taxes $          (11) 90 50 157 7 16 $         309
Net income (loss) attributable toSolventum $          (12) 75 38 129 5 13 $         249
Diluted EPS $       (0.07) 0.44 0.22 0.75 0.03 0.08 $        1.45
Effective tax rate (6.5) % 19.3 %
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum

Scroll to view ↔

Three months ended September 30, 2025
(Dollars in millions,except per shareamounts) GAAP Amortizationof acquisition-relatedintangibleassets Restructuringcosts (a) 3M spin-off and separation-relatedcosts (b) Certainlitigation-relatedcosts (c) Acquisitionand divestiture-related (d,e) Loss on debtextinguish-ment,net, (f) Non-GAAP
Net sales $    2,096 — — — — — — $     2,096
Cost of sales (5) $       961 — 2 (37) — — — $        926
Gross margin % 54.2 % — % (0.1) % 1.8 % — % — % — % 55.8 %
Selling, general andadministrative expenses $       780 (41) (4) (120) (2) (18) $        — $        595
Research anddevelopment expenses $       183 (36) — (3) — — — $        144
Operating expenses (6) $       963 (77) (4) (123) (2) (18) — $        739
Operating Income $    1,690 77 2 160 2 (1,500) — $        431
Operating incomemargin % 80.6 % 3.7 % 0.1 % 7.6 % 0.1 % (71.6) % — % 20.6 %
Non-operating expense(income), net (7) $       176 — — — — — (82) $          94
Income before incometaxes $    1,514 77 2 160 2 (1,500) 82 $        337
Net income (loss)attributable to Solventum $    1,266 65 1 123 2 (1,256) 62 $        263
Diluted EPS $      7.22 0.37 — 0.71 0.01 (7.16) 0.35 $       1.50
Effective tax rate 16.4 % 21.8 %
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum

Scroll to view ↔

(a) 2026 restructuring costs primarily related to the Company's Transform for the Future program. Includes employee termination costs of $6 million and other costs of $44 million, which includes third-party consulting, asset write-downs and compensation for employees dedicated to the program. 2025 restructuring costs primarily relate to the Company's Solventum Way program. Includes employee termination costs of $5 million and other costs of $(3) million.
(b) Consists of costs specifically incurred in connection with the Company's separation from 3M.
(c) Consists of charges and recoveries related to certain litigation matters.
(d) Acquisition integration and separation related costs, including legal, finance and tax advisory services. 2026 primarily consists of integration costs related to the acquisition of Acera Surgical and costs associated with the planned separation of the Company's Health Information Systems business. 2025 consists of costs associated with the separation of the Company's Purification and Filtration business.
(e) Gain on sale of the Purification and Filtration business, net of applicable tax impacts.
(f) Premium paid and related expenses incurred in connection with tender of debt, net of gains from related interest rate hedging contracts.
5 Cost of sales is the combination of cost of product and cost of software and rentals line items from the Condensed Consolidated Statements of Income and represents the total Company's cost of sales.
6 Operating expenses is the combination of selling, general and administrative expenses and research and development expenses from the Condensed Consolidated Statements of Income and represents the total Company's other operating expenses.
7 Non-operating expense (income), net is the combination of interest expense, net, loss on debt extinguishment, net, and other expense (income), net line items from the Consolidated Statements of Income and represents the total Company's non-operating expense.

Scroll to view ↔

Solventum CorporationSUPPLEMENTAL FINANCIAL INFORMATIONNON-GAAP MEASURES – (CONTINUED)*(Unaudited)
Nine months ended September 30, 2026
(Dollars in millions, except pershare amounts) GAAP Amortization ofacquisition-relatedintangibleassets Restructuringcosts (a) 3M spin-off andseparation-relatedcosts (b) Certainlitigation-relatedcosts (c) Acquisition anddivestiture-related (d,e) Non-GAAP
Net sales $      6,165 — — — — — $      6,165
Cost of sales (5) $      2,720 — (21) (102) — (4) $      2,592
Gross margin % 55.9 % — % 0.3 % 1.7 % — % 0.1 % 57.9 %
Selling, general and administrativeexpenses $      2,567 (126) (107) (356) (178) (27) $      1,773
Research and developmentexpenses $         548 (145) (4) (7) — (1) $         393
Operating expenses (6) $      3,115 (271) (111) (363) (178) (27) $      2,166
Operating Income $         329 271 132 465 178 32 $      1,406
Operating income margin % 5.3 % 4.4 % 2.1 % 7.5 % 2.9 % 0.5 % 22.8 %
Non-operating expense (income),net (7) $         217 — — — — — $         217
Income before income taxes $         112 271 132 465 178 32 $      1,189
Net income (loss) attributable toSolventum $           93 227 101 370 135 25 $         951
Diluted EPS $        0.54 1.31 0.58 2.13 0.78 0.14 $        5.48
Effective tax rate 17.1 % 20.0 %
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum

Scroll to view ↔

Nine months ended September 30, 2025
(Dollars in millions,except per shareamounts) GAAP Amortizationof acquisition-relatedintangibleassets Restructuringcosts (a) 3M spin-offandseparation-relatedcosts (b) Certainlitigation-relatedcosts (c) Acquisitionanddivestiture-related (d,e) Loss on debtextinguish-ment,net, (f) Non-GAAP
Net sales $    6,327 — — — — — $        — $    6,327
Cost of sales (5) $    2,903 — (9) (98) — — $        — $    2,796
Gross margin % 54.1 % — % 0.1 % 1.5 % — % — % — % 55.8 %
Selling, general andadministrative expenses $    2,321 (126) (14) (323) (29) (49) $        — $    1,780
Research anddevelopment expenses $       564 (110) (5) (11) — — $        — $       439
Operating expenses (6) $    2,885 (235) (19) (335) (29) (49) $        — $    2,218
Operating Income $    2,057 235 28 433 29 (1,469) $        — $    1,312
Operating income margin % 32.5 % 3.7 % 0.4 % 6.8 % 0.5 % (23.2) % — % 20.7 %
Non-operating expense(income), net (7) $       402 — — — — — $       (82) $       320
Income before incometaxes $    1,655 235 28 433 29 (1,469) 82 $       992
Net income (loss)attributable to Solventum $    1,493 199 21 333 22 (1,335) 62 $       794
Diluted EPS $      8.53 1.14 0.12 1.90 0.13 (7.62) 0.35 $      4.53
Effective tax rate 9.8 % 20.0 %
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum

Scroll to view ↔

(a) 2026 restructuring costs primarily relate to the Company's Transform for the Future program. Includes employee termination costs of $23 million and other costs of $109 million, which includes third-party consulting, asset write-downs and compensation for employees dedicated to the program. 2025 restructuring costs primarily related to the Company's Solventum Way program. Includes employee termination costs of $28 million.
(b) Consists of costs specifically incurred in connection with the Company's separation from 3M.
(c) Consists of charges and recoveries related to certain litigation matters.
(d) Acquisition integration and separation related costs, including legal, finance and tax advisory services. 2026 primarily consists of integration costs related to the acquisition of Acera Surgical, including amortization of inventory step-up and costs associated with the planned separation of the Company's Health Information Systems business. 2025 consists of costs associated with the separation of the Company's Purification and Filtration business.
(e) Gain on sale of the Purification and Filtration business, net of applicable tax impacts.
(f) Premium paid and related expenses incurred in connection with tender of debt, net of gains from related interest rate hedging contracts.
5 Cost of sales is the combination of cost of product and cost of software and rentals line items from the Consolidated Statements of Income and represents the total Company's cost of sales.
6 Operating expenses is the combination of selling, general and administrative expenses and research and development expenses from the Consolidated Statements of Income and represents the total Company's other operating expenses.
7 Non-operating expense (income), net is the combination of interest expense, net, loss on debt extinguishment, net, and other expense (income), net line items from the Consolidated Statements of Income and represents the total Company's non-operating expense.

**Solventum Corporation
****SUPPLEMENTAL FINANCIAL INFORMATION
****NON-GAAP MEASURES – (CONTINUED)*
**(Unaudited)

Free Cash Flow (non-GAAP measure):

Free cash flow is not defined under U.S. GAAP. Therefore, it should not be considered a substitute for income or cash flow data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. The Company defines free cash flow as net cash provided by (used in) operating activities less purchases of property, plant and equipment. It should not be inferred that the entire free cash flow amount is available for discretionary expenditures. The Company believes free cash flow is meaningful to investors as it is a useful measure of liquidity and the Company uses this measure as an indication of the strength of the Company and its ability to generate cash. Free cash flow varies across quarters throughout the year. Below find a recap of free cash flow.

Scroll to view ↔

(Dollars in millions) Three months ended September 30, Nine months ended September 30,
Major GAAP cash flow categories 2026 2025 2026 2025
Net cash provided by operating activities $          177 $             75 $          215 $           274
Net cash used in investing activities (80) 3,766 (244) 3,542
Net cash used in financing activities $           (51) $       (2,693) $         (401) $       (2,942)
Free cash flow (non-GAAP measure)
Net cash provided by operating activities $          177 $             75 $          215 $           274
Purchases of property, plant and equipment (80) (97) (247) (316)
Free cash flow $            97 $            (22) $           (32) $            (42)
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum

View original content to download multimedia:https://www.prnewswire.com/news-releases/solventum-reports-third-quarter-2026-financial-results-302931277.html

SOURCE Solventum

Released November 5, 2026

Events & presentations Bull 0 Bear 0 Routine

Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*

October 19, 2026 4:05pm EDT Download as PDF

  • First-of-its-kind clearance combines two advanced wound care technologies into one path for active healing to help streamline care and improve patient outcomes

  • Clearance pairs innovative synthetic electrospun fiber matrix technology with an industry-leading negative pressure wound therapy to optimize healing

EAGAN, Minn., Oct. 19, 2026 /PRNewswire/ -- Solventum

 (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata™ Synthetic Electrospun Fiber Matrix and Solventum™ V.A.C.® Therapy*. Following Solventum's acquisition of Acera Surgical in December 2025, this regulatory milestone brings two advanced technologies together into one path to support active wound healing.

"We're focused on delivering meaningful innovation that helps healthcare providers address clinical challenges and supports patients as they return to daily life," said Kelley Moffett, president of Advanced Wound Care at Solventum. "By combining Restrata™ Matrix's technology with our trusted V.A.C.® Therapy, we're giving clinicians an effective way to streamline care and support better patient outcomes."

Restrata Matrix and V.A.C.® Therapy are engineered to support various stages of the healing journey:

  • Restrata is a 100% synthetic, fully resorbable matrix engineered to support soft tissue healing. It supports tissue formation through structural cues rather than growth factors to create the foundation for soft tissue repair. Built to perform in challenging wound environments and resist enzymatic degradation, Restrata Matrix allows for cellular infiltration, neovascularization and organized collagen deposition. It degrades via hydrolysis over time, leaving native tissue behind.

  • V.A.C.® Therapy delivers negative pressure wound therapy (NPWT) to create an environment that promotes wound healing. When used with dressings like Solventum™ V.A.C.® Peel and Place Dressing, V.A.C.® Therapy helps maintain close contact between the matrix and the wound bed. Macrostrain draws wound edges together while microstrain stimulates cell proliferation, angiogenesis and granulation tissue formation. It promotes perfusion, reduces edema and removes fluid and infectious material for up to seven days per application.

"Complex wounds require clinicians to support tissue repair while also maintaining the right healing environment," said Matthew MacEwan, Ph.D., chief science officer and co-founder of Acera Surgical. "This indication brings those needs together in a single approach, giving clinicians another option to support healing more effectively across the course of care."

Applied together, Restrata Matrix provides structural support for soft tissue repair, while V.A.C.® Therapy helps create an optimized environment that supports tissue integration. Restrata Matrix's fully synthetic profile enables resistance to enzymatic degradation and aligns with V.A.C.® Peel and Place Dressing's wear time of up to seven days, whereas many collagen-based dressings degrade prematurely and therefore aren't optimal for concomitant use. Together, these therapies may allow for fewer dressing changes, less disruption to the healing environment and a more predictable workflow for care teams. Solventum is committed to expanding adoption of advanced wound healing technologies to help improve patient outcomes and advance more efficient care.

"Restrata Matrix and V.A.C.® Therapy can succeed even in the most complex wound environments," said Dr. Luis Fernandez, professor of surgery at The University of Texas at Tyler. "With Restrata Matrix, I consistently see significant granulation tissue growth within a few days, even in the most challenging cases. Combining Restrata Matrix with V.A.C.® Therapy provides an even greater opportunity to promote healing and improve patient outcomes."

To learn more about this next generation of advanced wound healing, visit go.Solventum.com/AdvancedWoundHealing

Prompts

Solventum Corporation (ticker SOLV), listed in United States.

Company History

Date Change Detail
Mar 15, 2023 Renamed 3M Health Care Co → SOLVENTUM CORP

ETFs Holding Solventum Corporation

ETF Weight in ETF Shares Market value As of
DUSA 2.11% 314,051 $ 26.833M Jul 31, 2026
DWLD 1.82% 130,541 $ 11.153M Jul 31, 2026
AQEC 1.52% 113,049 $ 8.722M Jun 30, 2026
HWSM 1.04% 370 $ 28.546K Jun 30, 2026
SMIZ 0.48% 14,574 $ 1.327M Aug 31, 2026
DFAT 0.29% 1,036,290 $ 92.033M Nov 12, 2026
EBI 0.28% 21,107 $ 1.922M Aug 31, 2026
AIVL 0.26% 14,169 $ 1.093M Jun 30, 2026
VFQY 0.24% 13,261 $ 1.208M Aug 31, 2026
VFMF 0.17% 18,299 $ 1.666M Aug 31, 2026
AVMC 0.14% 8,701 $ 771.344K Nov 16, 2026
SEIV 0.12% 21,999 $ 1.697M Jun 30, 2026
GVLU 0.10% 2,976 $ 263.822K Nov 17, 2026
MSSM 0.08% 6,189 $ 563.57K Aug 31, 2026
VFVA 0.07% 7,831 $ 713.091K Aug 31, 2026
THRO 0.06% 71,285 $ 6.319M Nov 16, 2026
GSPY 0.06% 4,335 $ 384.298K Nov 17, 2026
CAPE 0.05% 1,606 $ 123.903K Jun 30, 2026
DFUV 0.05% 82,381 $ 7.316M Nov 12, 2026
LGDX 0.04% 681 $ 60.371K Nov 17, 2026
DFSU 0.04% 10,503 $ 932.771K Nov 12, 2026
SYZ 0.04% 333 $ 25.691K Jun 30, 2026
DFAU 0.04% 53,961 $ 4.792M Nov 12, 2026
VSLU 0.04% 2,571 $ 198.353K Jun 30, 2026
DXUV 0.04% 25,090 $ 2.228M Nov 12, 2026
DFAC 0.03% 335,495 $ 29.795M Nov 12, 2026
DCOR 0.03% 156,802 $ 13.926M Nov 12, 2026
DFUS 0.02% 48,999 $ 4.352M Nov 12, 2026
AVLC 0.02% 3,039 $ 269.407K Nov 16, 2026
DFAS 0.02% 69,433 $ 6.166M Nov 12, 2026
HCMT 0.02% 1,024 $ 87.491K Jul 31, 2026
ACVF 0.01% 223 $ 19.053K Jul 31, 2026
DFVX 0.01% 664 $ 58.97K Nov 12, 2026
AVUS 0.01% 12,852 $ 1.139M Nov 16, 2026
CSHP 0.01% 224 $ 19.858K Nov 16, 2026
JUSA 0.01% 568 $ 48.882K Nov 17, 2026
DFLV 0.00% 3,908 $ 347.069K Nov 12, 2026
DUHP 0.00% 4,094 $ 363.588K Nov 12, 2026
NPFE 0.00% 50 $ 4,272.00 Jul 31, 2026
AVSU 0.00% 194 $ 17.198K Nov 16, 2026
IALT short 0.00% -3,916 $ -347.153K Nov 16, 2026
CORO 0.00% 91 $ 8,091.11 Nov 16, 2026